Baird Financial Group’s Pacira BioSciences PCRX Stock Holding History

Baird Financial Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$213K	Buy	+8,406	New	+$199K	﹤0.01%	1852
2019 Q2	–	Sell	-6,440	Closed	-$245K	–	1551
2019 Q1	$245K	Sell	6,440 -6,540	-50%	-$255K	﹤0.01%	1197
2018 Q4	$558K	Buy	12,980 +6,949	+115%	+$324K	﹤0.01%	954
2018 Q3	$288K	Buy	+6,031	New	+$261K	﹤0.01%	1189
2018 Q1	–	Sell	-5,794	Closed	-$264K	–	1284
2017 Q4	$264K	Sell	5,794 -35	-0.6%	-$1.39K	﹤0.01%	1156
2017 Q3	$219K	Buy	5,829 +474	+9%	+$19.1K	﹤0.01%	1164
2017 Q2	$255K	Buy	5,355 +142	+3%	+$6.59K	﹤0.01%	1127
2017 Q1	$238K	Buy	+5,213	New	+$225K	﹤0.01%	1127

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's PCRX Position: Q2 2026 in Review

Baird Financial Group opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 8,406 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #1852 among its holdings. This is a return to the name: Baird Financial Group previously reported a position in PCRX as recently as Q1 2019.

Baird Financial Group first reported a position in PCRX in Q1 2017 and has held it in 8 quarters since. The position peaked at $558K in Q4 2018. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Baird Financial Group held 8,406 shares of Pacira BioSciences worth $213K as of Q2 2026.
Pacira BioSciences was a new Baird Financial Group position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1852 holding.
Baird Financial Group first reported a position in Pacira BioSciences in Q1 2017 and has held it in 8 quarters since.
Baird Financial Group's Pacira BioSciences position peaked at $558K in Q4 2018.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.